x min read

GB Sciences Inc (OTCMKTS:GBLX) Has Multiple Catalysts Ahead

GB Sciences Inc (OTCMKTS:GBLX) Has Multiple Catalysts Ahead
Written by
Richard Sandle
Published on
July 6, 2017
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

While many cannabis related companies are mostly focused on fulfilling the demand for cannabis, be it medicinal or recreational, GB Sciences Inc (OTCMKTS:GBLX) is intensely focused on research and development of pharmaceutical grade medication that can potentially be derived from cannabis.GB Sciences Inc seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies. Although the Company believes that maximum shareholder value will ultimately be achieved through the development, production and marketing of certified cannabinoid medicines, therapies and treatments, in order to generate cash flow and near term profitability, the Company intends to cultivate and dispense cannabis for medical purposes in both Nevada and other states which permit such sales, and in which the Company and its operating partners are able to obtain cultivation and dispensing licenses. the Company seeks to become a trusted producer of consistent and efficacious medicinal strains and products, combining both cannabinoids and terpenes, which the Company intends to market in those states within the United States and in other countries where the sale of medical cannabis products are permitted. In addition, subject to obtaining Food and Drug Administrative (FDA) certification, the Company intends to market its cannabinoid based drug discoveries on a world-wide basis.On May 23, 2017 GB Sciences Inc announced the filing of its latest patent application by its wholly-owned subsidiary, Growblox Life Sciences, LLC for the treatment of chronic pain and heart therapies based on myrcene-containing complex mixtures. The Company’s current drug discovery efforts were accelerated through the powerful combination of GB Sciences' proprietary in silico prediction approach, termed the GB Sciences' Network Pharmacology Platform ("NPP"), and GB Sciences' proven high-throughput screening techniques using cell-based models. The current provisional patent application covers myrcene-containing complex mixtures capable of targeting the non-traditional cannabinoid receptor, TRPV1. The latest patent application complements the issued TRPV1 patent that GB Sciences licensed from Makai Biotechnology in December of 2016. John Poss, Chairman and CEO of GB Sciences, Inc. explains:

"These new chronic pain and heart formulas adhere to GB Science's strategy of commercializing complex mixtures of cannabis-derived compounds whose pharmaceutical activity does not require THC. Instead, the purified THC is sold as a certified raw ingredient or used in co-branded dispensary products."

GB Sciences Inc announced on June 26, 2017 that it secured a bid to Louisiana State University (LSU) and has received authorization from the LSU Board of Supervisors to proceed with contract negotiations to act as the LSU Agricultural Center's (AgCenter) licensed operator of their medical cannabis production facility as outlined in the Alison Neustrom Act (hereinafter referred to as the "Act"). The secured bid will enable GB Sciences to be the sole vendor of cannabis and extracted cannabis compounds on behalf of LSU for the patients of Louisiana. The agricultural centers at LSU and Southern University have the only two licenses granted by the State of Louisiana to cultivate, distribute, and sell medical cannabis.The Act specifically authorizes the LSU AgCenter to conduct research on medical cannabis. The AgCenter will operate a separate independent research division alongside and in the same facility as the Production Entity's commercial operation, which will produce therapeutic medical cannabis products for qualified patients of Louisiana. GB Sciences will have first rights to commercialize any inventions or discovery of the research. John Poss, Chairman and CEO of GB Sciences, Inc. commented:

"This is groundbreaking news and a tremendous opportunity. Now that approval from the Louisiana State University Board of Supervisors has been received, contract negotiations will commence and should be completed within the next 30 days. Then we can begin the real work."

In other news, the Company announced the appointment of Mr. Leslie Bocskor as Vice Chairman, effective April 28, 2017. Bocskor has been a director of GB Sciences since May 2016, and in this role has been instrumental in the Company's capital formation process and in the Company's relationship with its investment bank.Perhaps the most important news, yet least profound, is the announcement on May 16, 2017 that the initial harvest at its Cultivation Lab facility in Las Vegas, Nevada had commenced. This marks the beginning of the Company's revenue stream. When fully operational, the facility is expected to generate approximately $10 million in annual revenue.

GBLX stock has not had much movement since our last review on May 11, 2017. The stock is currently trading at $.2979. Nor have there been any new financial reports released. Current market capitalization stands at $37.50 million, on 125.87 million shares outstanding as of July 5, 2017.Any company that announces the acquisition of drug patents, and affiliations with prestigious academic institutions will capture the attention of investors. However, until these favorable press releases translate into revenues and profits, investors will only give the company a glance, and then move on. What’s important for GB Sciences Inc is that it will begin to report revenue. We will be updating our subscribers as soon as we know more. For the latest updates on GBLX, sign up below!Be sure to check out our complete coverage of GBLX.Image courtesy of macrocannabis via FlickrDisclosure: We have no position in GBLX and have not been compensated for this article.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.